Evaluation Of The Bnt162B2 COVID-19 Vaccine In Children 5 To 11 Years Of Age

This journal article details that a COVID-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age.